Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Riccardo Patacchini

Showing results (21-30 of 61) with videos related to

Pageof 7
Sort By:
Cancer Research|March 13, 2013
Novel therapeutic strategy to prevent chemotherapy-induced persistent sensory neuropathy by TRPA1 blockadeGabriela Trevisan, Serena Materazzi, Camilla Fusi, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 9, 2008
Cox-dependent fatty acid metabolites cause pain through activation of the irritant receptor TRPA1Serena Materazzi, Romina Nassini, Eunice Andrè, et al.
Bioorganic & Medicinal Chemistry Letters|August 6, 2002
Design, synthesis and biological activity of carbohydrate-containing peptidomimetics as new ligands for the human tachykinin NK-2 receptorGiuseppe Capozzi, Sabrina Giannini, Stefano Menichetti, et al.
Journal of Medicinal Chemistry|July 26, 2002
Monocyclic human tachykinin NK-2 receptor antagonists as evolution of a potent bicyclic antagonist: QSAR and site-directed mutagenesis studiesAlessandro Giolitti, Maria Altamura, Francesca Bellucci, et al.
Frontiers in Pharmacology|November 11, 2024
Corrigendum: CHF6297: a novel potent and selective p38 MAPK inhibitor with robust anti-inflammatory activity and suitable for inhaled pulmonary administration as dry powderCataldo Martucci, Andrew Dennis Allen, Nadia Moretto, et al.
British Journal of Pharmacology|June 7, 2005
Hydrogen sulfide causes vanilloid receptor 1-mediated neurogenic inflammation in the airwaysMarcello Trevisani, Riccardo Patacchini, Paola Nicoletti, et al.
Frontiers in Pharmacology|March 29, 2024
CHF6297: a novel potent and selective p38 MAPK inhibitor with robust anti-inflammatory activity and suitable for inhaled pulmonary administration as dry powderCataldo Martucci, Andrew Dennis Allen, Nadia Moretto, et al.
Journal of Medicinal Chemistry|November 11, 2005
Urotensin-II receptor ligands. From agonist to antagonist activityPaolo Grieco, Alfonso Carotenuto, Pietro Campiglia, et al.
Pflugers Archiv : European Journal of Physiology|January 20, 2012
TRPA1 and TRPV4 mediate paclitaxel-induced peripheral neuropathy in mice via a glutathione-sensitive mechanismSerena Materazzi, Camilla Fusi, Silvia Benemei, et al.
Plos One|September 16, 2015
Functional Characterization of Human ProNGF and NGF Mutants: Identification of NGF P61SR100E as a "Painless" Lead Investigational Candidate for Therapeutic ApplicationsFrancesca Malerba, Francesca Paoletti, Bruno Bruni Ercole, et al.
Pageof 7

Showing results (21-30 of 61) with videos related to

Sort By:
Pageof 7
Cancer Research|March 13, 2013
Novel therapeutic strategy to prevent chemotherapy-induced persistent sensory neuropathy by TRPA1 blockadeGabriela Trevisan, Serena Materazzi, Camilla Fusi, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 9, 2008
Cox-dependent fatty acid metabolites cause pain through activation of the irritant receptor TRPA1Serena Materazzi, Romina Nassini, Eunice Andrè, et al.
Bioorganic & Medicinal Chemistry Letters|August 6, 2002
Design, synthesis and biological activity of carbohydrate-containing peptidomimetics as new ligands for the human tachykinin NK-2 receptorGiuseppe Capozzi, Sabrina Giannini, Stefano Menichetti, et al.
Journal of Medicinal Chemistry|July 26, 2002
Monocyclic human tachykinin NK-2 receptor antagonists as evolution of a potent bicyclic antagonist: QSAR and site-directed mutagenesis studiesAlessandro Giolitti, Maria Altamura, Francesca Bellucci, et al.
Frontiers in Pharmacology|November 11, 2024
Corrigendum: CHF6297: a novel potent and selective p38 MAPK inhibitor with robust anti-inflammatory activity and suitable for inhaled pulmonary administration as dry powderCataldo Martucci, Andrew Dennis Allen, Nadia Moretto, et al.
British Journal of Pharmacology|June 7, 2005
Hydrogen sulfide causes vanilloid receptor 1-mediated neurogenic inflammation in the airwaysMarcello Trevisani, Riccardo Patacchini, Paola Nicoletti, et al.
Frontiers in Pharmacology|March 29, 2024
CHF6297: a novel potent and selective p38 MAPK inhibitor with robust anti-inflammatory activity and suitable for inhaled pulmonary administration as dry powderCataldo Martucci, Andrew Dennis Allen, Nadia Moretto, et al.
Journal of Medicinal Chemistry|November 11, 2005
Urotensin-II receptor ligands. From agonist to antagonist activityPaolo Grieco, Alfonso Carotenuto, Pietro Campiglia, et al.
Pflugers Archiv : European Journal of Physiology|January 20, 2012
TRPA1 and TRPV4 mediate paclitaxel-induced peripheral neuropathy in mice via a glutathione-sensitive mechanismSerena Materazzi, Camilla Fusi, Silvia Benemei, et al.
Plos One|September 16, 2015
Functional Characterization of Human ProNGF and NGF Mutants: Identification of NGF P61SR100E as a "Painless" Lead Investigational Candidate for Therapeutic ApplicationsFrancesca Malerba, Francesca Paoletti, Bruno Bruni Ercole, et al.
Pageof 7